Deborah D Bauwens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Deborah D Bauwens has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anne A D’hombres
Department of Radiotherapy, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France
1 shared publication - Anne-Sophie Michallet
Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France
1 shared publication - Bertrand Coiffier
Department of Hematology, Hospices Civils de Lyon, Lyon, France
1 shared publication - Christelle C Tychyj-Pinel
Department of Radiology and Nuclear Medicine, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France
1 shared publication - Fadhela F Bouafia-Sauvy
Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France
1 shared publication - Françoise Berger
Service d'urologie, université de l'hôpital d'Édouard-Herriot, hospices civils de Lyon, 5, place d'Arsonval, 69003 Pierre-Bénite, France
1 shared publication
Latest Publications
- Open Access
- 1 July 2013
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 6 (1) , 45
Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?
Less than 20% of patients with follicular lymphoma (FL) present with Ann Arbor Stage I or II disease at diagnosis. Numerous therapeutic options exist, however radiation therapy is considered the standard of care for early-stage disease based on single-institution or retrospective series. Our aim was to revisit the outcome of patients with localized FL in the rituximab era.
- 1 July 2013
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 6 (1) , 45
Open AccessEarly stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?
Less than 20% of patients with follicular lymphoma (FL) present with Ann Arbor Stage I or II disease at diagnosis. Numerous therapeutic options exist, however radiation therapy is considered the standard of care for early-stage disease based on single-institution or retrospective series. Our aim was to revisit the outcome of patients with localized FL in the rituximab era.